Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Tectonic Therapeutic, Inc. (TECX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.30+6.95%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TECX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress Phase 2 readout for TX45 and advance TX2100 into clinical development | It aims to advance Phase 2 readout for TX45 and start clinical development of TX2100. | Intact | failure to achieve Phase 2 readout for TX45 or clinical start of TX2100 by 2028-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year view is still in a watch state: management has advanced key trials, but evidence of financial strength remains limited.
The snapshot provides no valuation or expectations data, so whether TECX is cheap or expensive versus peers cannot be assessed. The market’s assumptions are also unclear; confidence in this evidence is low.
Near term, ongoing losses and weak recent performance leave TECX exposed to execution and industry risks, despite an August earnings beat following a May miss. Management reports lower quarterly losses and expense control, while cash declined but the stated runway extended to Q1 2029. Trial progress is tangible, but the next major evidence point is expected TX45 topline data in early Q1 2027.
The multi-year thesis depends on clinical progress, especially the TX45 results and continued development of TX2100, alongside enough cash to fund operations. Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strength among healthcare bellwethers could support the sector backdrop.
Over the next 1 to 3 years, TECX’s long-term thesis rests on clinical milestones and runway management, with ongoing losses and elevated risk still central. Evidence is limited and confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: ““In the second quarter, we completed enrollment in our global APEX Phase 2 trial in PH-HFpEF, a critical milestone for TX45, and we look forward to topline results in early Q1 2027,” said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic.” ““We are very excited about our TX2100 clinical program as a potential first-in-class, selective anti-angiogenic therapy for HHT, a disease with no approved treatments,” said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic.”
Limit operating losses while advancing clinical programs | Management is focused on controlling expenses amid ongoing losses. | Intact | operating losses worsen beyond -$27.3M per quarter | Operating income: $-24.218M FY2026-Q2; GAAP. Published target: Operating losses not worsening beyond -$27.3M per quarter. Target period is not explicitly aligned with this observation. Aug 6, 2026-24,218,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The increase was primarily the result of contract research and contract development and manufacturing organizations costs related to the ongoing Phase 2 clinical trials of TX45 and employee-related expenses due to an increase in non-cash, stock-based compensation expense and increase in headcount.” “The increase was primarily the result of CRO and CDMO costs related to the ongoing Phase 2 clinical trial of TX45 and employee-related expenses due to an increase in non-cash, stock-based compensation expense and increase in headcount.” Delivery assessment Nov 4, 2026 |
Maintain cash runway through late 2028 to fund operations | Tectonic Therapeutic has a cash runway into late 2028 to fund clinical trials. | Intact | cash runway falls short of Q4 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-5.68 → $-5.32 · observed estimates
$0.00B → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-5.68 | $0 | 9 / 8 |
| 2026-07-25 | $-5.68 | $0 | 9 / 8 |
| 2026-07-26 | $-5.68 | Unavailable | 8 / 0 |
| 2026-07-27 | $-5.68 | $0 | 9 / 8 |
| 2026-07-28 | $-5.68 | $0 | 9 / 8 |
| 2026-07-29 | $-5.68 | Unavailable | 8 / 0 |
| 2026-07-30 | $-5.68 | Unavailable | 8 / 0 |
| 2026-07-31 | $-5.68 | $0 | 9 / 8 |
| 2026-08-01 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-02 | $-5.68 | $0 | 9 / 8 |
| 2026-08-03 | $-5.68 | $0 | 9 / 8 |
| 2026-08-04 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-05 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-06 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-08 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-09 | $-5.68 | $0 | 9 / 8 |
| 2026-08-10 | $-5.68 | $0 | 9 / 8 |
| 2026-08-12 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-13 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-14 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-15 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-16 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-17 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-18 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-19 | $-5.68 | Unavailable | 8 / 0 |
| 2026-08-20 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-21 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-22 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-23 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-24 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-25 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-26 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-27 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-28 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-29 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-30 | $-5.41 | Unavailable | 8 / 0 |
| 2026-08-31 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-01 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-02 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-03 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-04 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-05 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-06 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-07 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-08 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-09 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-10 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-11 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-12 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-13 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-14 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-15 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-16 | $-5.41 | Unavailable | 8 / 0 |
| 2026-09-17 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-18 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-19 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-20 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-21 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-22 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-23 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-24 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-25 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-26 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-27 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-28 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-29 | $-5.38 | Unavailable | 7 / 0 |
| 2026-09-30 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-01 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-02 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-03 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-04 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-05 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-06 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-07 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-08 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-09 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-10 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-11 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-12 | $-5.38 | Unavailable | 7 / 0 |
| 2026-10-13 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-14 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-15 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-16 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-17 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-18 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-19 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-20 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-21 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-22 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-23 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-24 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-25 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-26 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-27 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-28 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-29 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-30 | $-5.32 | Unavailable | 5 / 0 |
| 2026-10-31 | $-5.32 | Unavailable | 5 / 0 |
| 2026-11-01 | $-5.32 | Unavailable | 5 / 0 |
| 2026-11-02 | $-5.32 | Unavailable | 5 / 0 |
| 2026-11-03 | $-5.32 | Unavailable | 5 / 0 |
| 2026-11-04 | $-5.32 | Unavailable | 5 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.